Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | ANPEP | P15144 | 2/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15018685 | 1.00 | KDM1A (0.50) | KDM1AHTR2ASIGMAR1ANPEPGRIN2D | |
| SCHEMBL31349197 | 1.00 | KDM1A (0.50) | KDM1AHTR2ASIGMAR1ANPEPGRIN2D | |
| SCHEMBL13779890 | 1.00 | KDM1A (0.50) | KDM1AHTR2ASIGMAR1ANPEPGRIN2D | |
| SCHEMBL8068536 | 1.00 | KDM1A (0.50) | KDM1AHTR2ASIGMAR1ANPEPGRIN2D | |
| SCHEMBL30968147 | 1.00 | KDM1A (0.50) | KDM1AHTR2ASIGMAR1ANPEPGRIN2D | |
| SCHEMBL3196912 | 1.00 | KDM1A (0.50) | KDM1AHTR2ASIGMAR1ANPEPGRIN2D | |
| Hydrochloric Acid SCHEMBL2590934 | 0.98 | KDM1A (0.53) | KDM1AHTR2ASIGMAR1ANPEPGRIN2D | |
| SCHEMBL3228205 | 0.77 | KDM1A (0.47) | KDM1AHTR2ASIGMAR1ANPEPGRIN2D | |
| SCHEMBL1239150 | 0.77 | KDM1A (0.47) | KDM1AHTR2ASIGMAR1ANPEPGRIN2D | |
| SCHEMBL10557020 | 0.77 | KDM1A (0.47) | KDM1AHTR2ASIGMAR1ANPEPGRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029985-A1 | Process | AVECIA PHARMACEUTICALS LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| WO-2009037416-A1 | PROCESS FOR PREPARING SULPHONAMIDES | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2009-03-26 | — | — | WO | disclosed |
| US-20060252964-A1 | Process for the preparation of aromatic amines | AVECIA PHARMACEUTICALS LIMITED (GB) | 2006-11-09 | — | — | US | disclosed |
| EP-1210305-B1 | TRANSFER HYDROGENATION PROCESS | AVECIA PHARMACEUTICALS LTD (GB) | 2005-07-20 | — | — | EP | disclosed |
| US-6696608-B1 | PRODUCING PRIMARY OR SECONDARY AMINES FROM N-SUBSTITUTED IMINES AND IMINIUM SALTS | AVECIA LIMITED (GB) | 2004-02-24 | — | — | US | disclosed |
| EP-1117627-B1 | TRANSFER HYDROGENATION PROCESS | AVECIA LTD (GB) | 2003-05-28 | — | — | EP | disclosed |
| US-6509467-B1 | Of iminium salts using transition metal complex catalyst | AVECIA LIMITED (GB) | 2003-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029985-A1 | Process | ADH1A, ADH1C, AKR1C3 | KDM1A 1206/4885HTR2A 1435/4885SIGMAR1 483/4885 |
| US-20060252964-A1 | Process for the preparation of aromatic amines | TYR, PAH, NPR1 | KDM1A 176/4885HTR2A 299/4885SIGMAR1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.